Our Investment Managers
The risks inherent in cyber security vulnerabilities are finally being recognized, as businesses and governments scramble to shore up their defenses. In what remains a deeply fragmented market, the available technology is being used inappropriately or not at all. Despite an ever-mounting number of government initiatives, systems around the world remain critically exposed. Albany Investment’s Partners have been involved in this emerging sector for many years, and its new private offering is structured to take advantage of current market fragmentation. Albany invests in fast growing, innovative companies which have proven their capabilities as suppliers for UK Government security and law enforcement. The team‘s expertise will enable these companies to expand beyond their important but narrow public sector vertical and meet the global market’s demand for reliable cyber security solutions.
Platinum is a $20 billion Australia-based equity manager established in 1994. Platinum has one core investment style – to seek out companies whose true worth and prospects are yet to be fully recognized by the market. Historical results show that the approach has worked in different economic climates and withstood the test of business cycles. With a focus on achieving strong long-term absolute returns (rather than simply by comparison to a benchmark index), Platinum looks beyond short-term market turbulence caused by events of a transient nature to seek out ‘unfashionable’ companies whose actual worth is greater than the value implied in their present share price. Platinum offers: Global, Asia, Europe, and Japan long/short equity strategies, as well as sector focused strategies in Healthcare, Technology, and Consumer brands.
Rare genetic diseases are a significant burden on society through both uncurbable, often fatal genetic diseases in adults and children as well as a large cost on society through disability and childhood mortality. Existing therapeutic platforms do not address the issue adequately and are often symptomatic. Advanced biotherapeutics are key to addressing the challenges of modern-day healthcare – spiraling cost of long-term chronic illness and lack of cures. 4Bio is a London-based firm focused on private equity and venture capital in Life Sciences. 4Bio invests into advanced therapies addressing high unmet medical and social needs. 4Bio’s investment focus pertains to the largest segments across the new generation of therapeutic platforms including gene therapy, cell therapy, RNA-based therapy, targeted therapy, and microbiome.